Fang Fang1, Yu Zhang1,2, Jingjing Tang3, L Dade Lunsford4, Tiangui Li5, Rongrui Tang6, Jialing He1, Ping Xu7, Andrew Faramand4, Jianguo Xu1, Chao You1. 1. West China Hospital, Sichuan University, Chengdu, Sichuan, China. 2. Affiliated Hospital of Chengdu University, Chengdu, Sichuan, China. 3. Chinese University of Hong Kong, Shenzhen, Guangdong, China. 4. University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 5. Longquanyi Hospital, Chengdu, Sichuan, China. 6. Southwest Hospital, Army Medical University, Chongqing, China. 7. Sichuan University Library, Chengdu, Sichuan, China.
Abstract
Importance: Although corticosteroids are widely used for adults with sepsis, both the overall benefit and potential risks remain unclear. Objective: To conduct a systematic review and meta-analysis of the efficacy and safety of corticosteroids in patients with sepsis. Data Sources and Study Selection: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception until March 20, 2018, and updated on August 10, 2018. The terms corticosteroids, sepsis, septic shock, hydrocortisone, controlled trials, and randomized controlled trial were searched alone or in combination. Randomized clinical trials (RCTs) were included that compared administration of corticosteroids with placebo or standard supportive care in adults with sepsis. Data Extraction and Synthesis: Meta-analyses were conducted using a random-effects model to calculate risk ratios (RRs) and mean differences (MDs) with corresponding 95% CIs. Two independent reviewers completed citation screening, data abstraction, and risk assessment. Main Outcomes and Measures: Twenty-eight-day mortality. Results: This meta-analysis included 37 RCTs (N = 9564 patients). Eleven trials were rated as low risk of bias. Corticosteroid use was associated with reduced 28-day mortality (RR, 0.90; 95% CI, 0.82-0.98; I2 = 27%) and intensive care unit (ICU) mortality (RR, 0.85; 95% CI, 0.77-0.94; I2 = 0%) and in-hospital mortality (RR, 0.88; 95% CI, 0.79-0.99; I2 = 38%). Corticosteroids were significantly associated with increased shock reversal at day 7 (MD, 1.95; 95% CI, 0.80-3.11) and vasopressor-free days (MD, 1.95; 95% CI, 0.80-3.11) and with ICU length of stay (MD, -1.16; 95% CI, -2.12 to -0.20), the sequential organ failure assessment score at day 7 (MD, -1.38; 95% CI, -1.87 to -0.89), and time to resolution of shock (MD, -1.35; 95% CI, -1.78 to -0.91). However, corticosteroid use was associated with increased risk of hyperglycemia (RR, 1.19; 95% CI, 1.08-1.30) and hypernatremia (RR, 1.57; 95% CI, 1.24-1.99). Conclusions and Relevance: The findings suggest that administration of corticosteroids is associated with reduced 28-day mortality compared with placebo use or standard supportive care. More research is needed to associate personalized medicine with the corticosteroid treatment to select suitable patients who are more likely to show a benefit.
Importance: Although corticosteroids are widely used for adults with sepsis, both the overall benefit and potential risks remain unclear. Objective: To conduct a systematic review and meta-analysis of the efficacy and safety of corticosteroids in patients with sepsis. Data Sources and Study Selection: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception until March 20, 2018, and updated on August 10, 2018. The terms corticosteroids, sepsis, septic shock, hydrocortisone, controlled trials, and randomized controlled trial were searched alone or in combination. Randomized clinical trials (RCTs) were included that compared administration of corticosteroids with placebo or standard supportive care in adults with sepsis. Data Extraction and Synthesis: Meta-analyses were conducted using a random-effects model to calculate risk ratios (RRs) and mean differences (MDs) with corresponding 95% CIs. Two independent reviewers completed citation screening, data abstraction, and risk assessment. Main Outcomes and Measures: Twenty-eight-day mortality. Results: This meta-analysis included 37 RCTs (N = 9564 patients). Eleven trials were rated as low risk of bias. Corticosteroid use was associated with reduced 28-day mortality (RR, 0.90; 95% CI, 0.82-0.98; I2 = 27%) and intensive care unit (ICU) mortality (RR, 0.85; 95% CI, 0.77-0.94; I2 = 0%) and in-hospital mortality (RR, 0.88; 95% CI, 0.79-0.99; I2 = 38%). Corticosteroids were significantly associated with increased shock reversal at day 7 (MD, 1.95; 95% CI, 0.80-3.11) and vasopressor-free days (MD, 1.95; 95% CI, 0.80-3.11) and with ICU length of stay (MD, -1.16; 95% CI, -2.12 to -0.20), the sequential organ failure assessment score at day 7 (MD, -1.38; 95% CI, -1.87 to -0.89), and time to resolution of shock (MD, -1.35; 95% CI, -1.78 to -0.91). However, corticosteroid use was associated with increased risk of hyperglycemia (RR, 1.19; 95% CI, 1.08-1.30) and hypernatremia (RR, 1.57; 95% CI, 1.24-1.99). Conclusions and Relevance: The findings suggest that administration of corticosteroids is associated with reduced 28-day mortality compared with placebo use or standard supportive care. More research is needed to associate personalized medicine with the corticosteroid treatment to select suitable patients who are more likely to show a benefit.
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: Ann Intern Med Date: 2009-07-20 Impact factor: 25.391
Authors: Bo Hu; Jian-guo Li; Hui Liang; Qing Zhou; Zhui Yu; Lu Li; Yun Luo; Chang Liu; Quan Gan Journal: Zhongguo Wei Zhong Bing Ji Jiu Yi Xue Date: 2009-09
Authors: Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay Journal: Intensive Care Med Date: 2003-03-28 Impact factor: 17.440
Authors: Larissa Shamseer; David Moher; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart Journal: BMJ Date: 2015-01-02
Authors: Naser Alotaibi; Moudhi Alroomi; Wael Aboelhassan; Soumoud Hussein; Rajesh Rajan; Noor AlNasrallah; Mohammad Al Saleh; Maryam Ramadhan; Kobalava D Zhanna; Jiazhu Pan; Haya Malhas; Hassan Abdelnaby; Farah Almutairi; Bader Al-Bader; Ahmad Alsaber; Mohammed Abdullah Journal: Ann Med Surg (Lond) Date: 2022-06-29
Authors: Elizabeth W Tindal; Brandon E Armstead; Sean F Monaghan; Daithi S Heffernan; Alfred Ayala Journal: Expert Opin Ther Targets Date: 2021-04-12 Impact factor: 6.902
Authors: Fernanda Meira; Estela Moreno-García; Laura Linares; Irene Macaya; Adria Tomé; Marta Hernández-Meneses; Laia Albiach; Laura Morata; Laura Letona; Marta Bodro; Alberto Cózar-Llistó; Celia Cardozo; Mariana Chumbita; Cristina Pitart; Juan Ambrosioni; Verónica Rico; Daiana Agüero; Pedro Puerta-Alcalde; Nicole Garcia-Pouton; Francesc Marco; Carolina Garcia-Vidal; Alex Soriano; José Antonio Martínez Journal: Infect Dis Ther Date: 2021-06-11